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Abstract
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Bleeding is the most common complication of anticoagulant use. The evaluation and management
of the bleeding patient is a core competency of emergency medicine. As the prevalence of patients
receiving anticoagulant agents and variety of anticoagulants with different mechanisms of action,
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pharmacokinetics, indications, and corresponding reversal agents increase, physicians and other
clinicians working in the emergency department require a current and nuanced understanding of
how best to assess, treat, and reverse anticoagulated patients. In this project, we convened an
expert panel to create a consensus decision tree and framework for assessment of the bleeding
patient receiving an anticoagulant, as well as use of anticoagulant reversal or coagulation factor
replacement, and to address controversies and gaps relevant to this topic. To support decision tree
interpretation, the panel also reached agreement on key definitions of life-threatening bleeding,
bleeding at a critical site, and emergency surgery or urgent invasive procedure. To reach consensus
recommendations, we used a structured literature review and a modified Delphi technique by an
expert panel of academic and community physicians with training in emergency medicine,
cardiology, hematology, internal medicine/thrombology, pharmacology, toxicology, transfusion
medicine and hemostasis, neurology, and surgery, and by other key stakeholder groups.

Author Manuscript

INTRODUCTION
Background

Author Manuscript

Anticoagulants are used to prevent and treat thrombotic events associated with high
morbidity and mortality, such as atrial fibrillation, heart valve replacement, stroke, and
venous thromboembolism. They work by altering the normal physiology of the coagulation
cascade, resulting in decreased thrombin generation or direct thrombin inhibition. Their
main complication is bleeding, from self-limited to life threatening. Most patients with
bleeding complications present to the emergency department (ED) for care. Between 2013
and 2015, 17.6% of all patient presentations to the ED for adverse drug events were related
to anticoagulant use, the most common class of medications resulting in an adverse event,
and approximately half of these cases resulted in hospitalization.1 Recent studies estimate
that approximately 228,600 ED visits are due to anticoagulant issues. Bleeding represents
approximately 80% of these visits, which exclude fatal bleeding events that never involve
ED presentation.1,2

Author Manuscript

The use of anticoagulants has increased markedly in the past decade. Advances in diagnosis
and treatment of venous thromboembolism have led to an increase in the annual incidence of
first-time venous thromboembolism, from 73 per 100,000 patients in the mid-1980s to 133
per 100,000 patients in 2009.3 Some patients receive an anticoagulant for a short time, such
as those with a provoked deep venous thrombosis. However, recent evidence supports the
use of long-term anticoagulation in patients with either unprovoked venous
thromboembolism or provoked venous thromboembolism with ongoing risk factors.4–6
Anticoagulants also decrease the risk of ischemic stroke in patients with nonvalvular atrial
fibrillation.7 The incidence of atrial fibrillation increases with age, and the increasing
geriatric population is leading to larger cohorts of patients receiving long-term
anticoagulation. Expanding indications for anticoagulation include venous
thromboembolism prophylaxis in the medically complex and oncology patient populations
and those with chronic coronary artery disease or peripheral arterial disease.8–12 It is
estimated that 4 to 5 million US hospitalized medical patients may qualify for extended
venous thromboembolism thromboprophylaxis after discharge and that chronic coronary
artery disease and peripheral arterial disease affect 16.8 and 8.5 million Americans,
Ann Emerg Med. Author manuscript; available in PMC 2020 October 08.
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respectively.13,14 As anticoagulation becomes more common, the prevalence of
anticoagulated patients and associated bleeding events will increase.

Author Manuscript

Direct oral anticoagulants have overtaken vitamin K antagonists as preferred anticoagulants
for a broad number of indications. As of 2014, the majority of new anticoagulant initiations
have been with a direct oral anticoagulant.15–18 The number of patients treated with direct
oral anticoagulants has doubled during the past 3 years, from 3 million to 7.6 million.19
Direct oral anticoagulants offer several advantages over vitamin K antagonists, including
rapid onset of action, no heparin bridging requirement, short half-life, no routine monitoring,
minimal food-drug and drug-drug interactions, and decreased risk of major bleeding events,
especially intracranial and fatal ones, as well as noninferiority in preventing thrombotic
events.20–23 However, the lack of specific reversal agents for direct oral anticoagulants (until
October 2015 for dabigatran and May 2018 for apixaban and rivaroxaban) has been a
potential barrier to their use.24 Direct oral anticoagulants encompass several different
medications with a variety of targets and drug-specific reversal agents that have only
recently been available (Figure 1). Although vitamin K antagonists have been used since the
1940s and clinicians have familiarity treating their bleeding complications, some clinicians
may be less familiar with the most current evidence-based approaches.
Importance

Author Manuscript

The assessment and management of patients with bleeding and without it, but who require
emergency procedures, are complex. Clinicians must be familiar with the various
anticoagulants and how to rapidly stabilize and risk stratify patients, and, if indicated,
administer a reversal agent or factor replacement. Patients may not be capable of accurately
communicating the agent, dose, and timing of their anticoagulants. Laboratory tests to detect
the presence and effect of anticoagulants are not routinely accessible, and it is unclear
whether their results aid treatment (eg, although thrombin and Xa assays were used in trials,
reversal use was not predicated on assay results). Unique patient factors such as advanced
age, other medications (especially antiplatelet agents), and comorbidities (eg, renal or
hepatic dysfunction) must be recognized and considered. Reversal or replacement agents are
costly compared with other medications routinely administered in the ED setting; however,
their indications involve high-risk patients. Anticoagulated patients can be critically ill with
life-threatening bleeding or bleeding at a critical site, or may not be bleeding but require an
emergency surgery or procedure with high risk of bleeding that cannot be safely delayed.
The assessment and treatment of these patients are fraught with uncertainty and risk,
necessitating a decision framework to support timely and sound care.
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Definitions of a life-threatening bleeding event or critical site may vary significantly. Several
definitions for major bleeding exist in the literature from previous trials, such as
International Society and Haemostasis, Thrombolysis in Myocardial Infarction, Global
Utilization of Streptokinase and Tissue Plasminogen for Occluded Coronary Arteries,
Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial, Acute Catheterization
and Urgent Intervention Triage Strategy, Harmonizing Outcomes with Revascularization and
Stents in Acute Myocardial Infarction, Global Registry of Acute Coronary Events, and
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Platelet Inhibition and Patient Outcomes.25–33 Others have created universal definitions for
bleeding severity, such as the Bleeding Academic Research Consortium.34
Confusion persists between reversal (ie, anticoagulant is directly neutralized) and
replacement (ie, target clotting factors of the anticoagulant are repleted) strategies. The
logistics of administration and pharmacokinetics are significantly different. Current national
guidelines have not been updated to reflect the most recently approved reversal agents and
thus do not reflect current clinical practice (eg, Food and Drug Administration [FDA]
approval of andexanet alfa in May 2018).35 A reversal decision tool that provides the most
up-to-date recommendations, highlights the importance of emergency supportive care
measures, offers an approach to the risk stratification of patients for whom reversal or
replacement agents may benefit, and describes which therapies are likely or not likely to
benefit candidate patients would greatly aid clinicians.
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Goals of This Investigation
We seek to provide clinicians a consensus decision framework to be used as a bedside tool
for assessment and management of patients with bleeding and those without it but who
require emergency procedures.

MATERIALS AND METHODS
Study Design and Setting

Author Manuscript

The American College of Emergency Physicians (ACEP) convened an expert panel on
anticoagulation reversal. We performed a structured literature review examining the past
decade of publications and guidelines involving vitamin K antagonists, direct oral
anticoagulants, heparins, and the corresponding agents used for reversal or factor
replacement, including their respective efficacy, safety, and logistics of use. Although the
evidence was not graded, we emphasized studies used as the basis for FDA approval of
agents. When possible, definitions and recommendations reflected study criteria and
treatment processes; otherwise, we relied on the expert panel to standardize definitions and
processes. We used a modified Delphi technique to reach consensus.
Literature Review

Author Manuscript

The panel chairs consulted with medical librarians and performed a structured literature
review of PubMed, Scopus, and ClinicalTrials.gov to create a resource library for panel
members. The literature search focused on 2 main aspects of anticoagulant reversal or
replacement: clinical trials showing the effects of specific reversal or replacement agents,
and specialty society guidelines. We searched for key-word terms, shown in Tables E1 to E3
(available online at http://www.annemergmed.com). The panel chairs reviewed abstracts and
full articles to select those most relevant. This process yielded 55 clinical trial references and
54 guideline references. We provided panelists with access to the reference library and the
opportunity to make additions.
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Between July and December 2018, ACEP convened a multidisciplinary, geographically and
practice-setting diverse expert panel of clinicians (Table 1). ACEP staff selected the
cochairs, who in turn selected the panelists. Selection criteria included a publication history,
direct clinical experience in evaluation and management of the target patient population, or
both. To recruit community emergency physicians and advanced-practice provider-based
panelists, ACEP solicited participants through the ACEP Emergency Medicine Practice
Committee and Society of Emergency Medicine Physician Assistants, respectively.
Methods for Consensus

Author Manuscript

The Delphi technique is a recognized framework to reach a consensus based on a series of
iterative interactions and review of key questions.36 Four rounds of structured voting
occurred. The chairs presented results of the initial voting and facilitated extensive
discussion at in-person meetings (rounds 2 and 3) on September 17, 2018, and October 1,
2018. The fourth round involved one additional survey of panelist comments and votes. The
chairs modified the recommendations according to the previous rounds’ discussion and
voting. The final panel recommendations represent consensus and majority opinions.

RESULTS

Author Manuscript
Author Manuscript

The panel first focused on reaching agreement on the guidance statement for anticoagulant
reversal or factor replacement (Figure 2). We included parenteral agents in the figures and
tables because emergency physicians may encounter patients receiving them in addition to
oral agents (eg, oncology patient receiving enoxaparin for venous thromboembolism,
nursing facility resident treated with unfractionated heparin). We outlined the initial
assessment and performance of multiple cognitive and procedural tasks in parallel,
particularly determining the amount and last dose of anticoagulant, and the initiation of
emergency treatment and supportive care (Figure 3). Immediate supportive care is critical for
all patients whether or not a replacement or reversal agent is used. This includes source
control by compression, surgery, endoscopy, or interventional radiology. It is important not
to anchor on reversal or replacement strategies at the expense of these other critically
important actions. The intention of diagnostic testing at this point is to help risk stratify,
identify the extent and consequence of bleeding, and uncover contributing comorbid issues
(eg, hepatic/renal failure). Concurrent use of aspirin or a P2Y12 inhibitor (eg, clopidogrel,
ticagrelor, prasugrel) or parenteral agents (eg, enoxaparin for venous thromboembolism in
oncology patients) should be identified. Desmopressin may be useful in the treatment of
bleeding associated with antiplatelet agents. The benefit of platelet transfusion is unclear and
may in some critical-site bleeding events, such as nontraumatic intracerebral hemorrhage, be
harmful in the absence of significant thrombocytopenia.37
In anticoagulant-associated life-threatening or critical-site bleeding or nonbleeding requiring
emergency procedures, reversal or replacement agents in addition to supportive measures are
essential. Currently, only 2 reversal agents for oral anticoagulants are approved by the FDA:
idarucizumab for dabigatran and andexanet alfa for apixaban and rivaroxaban. These
specific reversal agents bind the active drug directly and inhibit the anticoagulant effect
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within minutes. Vitamin K antagonist replacement therapy has included vitamin K and 4factor prothrombin complex concentrate, 3-factor prothrombin complex concentrate,
activated prothrombin complex concentrate, recombinant factor VIIa, or fresh-frozen plasma
by replacing factors of the coagulation cascade rather than reversing the anticoagulant.
However, the FDA has approved only one agent, the 4-factor prothrombin complex
concentrate Kcentra, for this purpose. For the patient receiving a direct oral anticoagulant,
replacement with prothrombin complex concentrate or activated prothrombin complex
concentrate is presumed to overwhelm the Xa or direct thrombin inhibitor and restore
hemostasis. However, supporting evidence is limited: the studies are small case studies or
series, have a convenience population without prespecified inclusion or endpoint criteria,
and lack FDA approval.38,39 Therefore, we suggest prothrombin complex concentrate for
direct oral anticoagulant treatment only if first-line reversal agents (eg, idarucizumab,
andexanet alfa) are unavailable. In such cases, 4-factor prothrombin complex concentrate is
preferred over 3-factor prothrombin complex concentrate, although clinical data are limited.
40,41

Author Manuscript

Defining which patients benefit from reversal or replacement strategies is pivotal (Figure 4).
Risk stratification is ubiquitous in emergency medicine and applies to the bleeding patient
receiving anticoagulants or the nonbleeding patient who overdosed or needs an emergency
procedure. In the bleeding patient, the most significant risks are life-threatening bleeding
events and critical-site bleeding events, both traumatic and nontraumatic. A modified
definition of Bleeding Academic Research Consortium type 3 bleeding to define a lifethreatening bleeding event is based on laboratory values or vital sign abnormalities
attributable to bleeding that also prompts interventions such as transfusions or use of
vasoactive medications. Critical sites are based on space-occupying lesions and the predicted
morbidity and mortality of hemorrhage (eg, brain, spine). Risk stratification includes clinical
context; specifically, the dose and most recent time an anticoagulant was received. For
example, a small traumatic subarachnoid hemorrhage with a normal neurologic examination
result, associated with a direct Xa inhibitor with a short half-life received more than 2 halflives ago, may not require a reversal agent. Alternatively, a large intracranial bleeding event
with midline shift and National Institutes of Health Stroke Scale score greater than 22 is
catastrophic. Use of a replacement or reversal agent would likely be futile and therefore it
may be withheld.
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Reversal or replacement carries some risks in addition to cost; patients are returned to their
baseline prothrombotic state after administration and could therefore experience a
thrombotic event.42,43 Reevaluation of critically ill, high-risk patients has dynamic clinical
courses and requires frequent reassessments, especially after treatment with a replacement or
reversal agent (Figure 5). Bleeding patients not responding as expected may have additional
ongoing processes, such as disseminated intravascular coagulopathy, disseminated
intravascular coagulopathy-like syndromes, or traumatic coagulopathies. Reassessment to
evaluate for other causes of hemorrhage may include additional or repeated laboratory or
imaging studies. Redosing of reversal or replacement agents is controversial because
supporting evidence is lacking. However, in the unstable patient with a worsening course,
redosing could be indicated, although off label, because the reversal agents’ half-life is
shorter than that of the targeted anticoagulant. We detail the key mechanisms of action,
Ann Emerg Med. Author manuscript; available in PMC 2020 October 08.
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metabolism, timing, and dosing for the most common anticoagulants and their
corresponding reversal or replacement agents in Tables 2 and 3.
Complementary treatment strategies include tranexamic acid. The most compelling evidence
for tranexamic acid is in traumatic or gynecologic and obstetric hemorrhage.44,45 Case
reports suggest that topical or nebulized tranexamic acid can be an effective adjunct in ear,
nose, and throat bleeding, such as epistaxis, dental bleeding, or post-tonsillectomy bleeding.
46,47 Although tranexamic acid is inexpensive, widely available, and a well-tolerated
treatment with minimal thrombotic risks, there are insufficient data to establish a role for it
outside of these scenarios.48–50

Author Manuscript
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Nonbleeding anticoagulated patients with either intentional (eg, suicide attempt) or
unintentional overdose (eg, acute renal dysfunction, drug-drug interaction, medication error)
present unique considerations. Data supporting activated charcoal in overdose of an oral
anticoagulant are poor, and it should be considered only in cooperative fully awake patients
(eg, obviating the need for a nasogastric tube) who present within 1 to 2 hours of acute
ingestion without anticipated need for endoscopy.51 Patients should be monitored for 2 to 5
half-lives of the applicable agent according to renal and hepatic function, drug
pharmacokinetics, coingestants, comorbidities, and clinical status. Patients receiving
warfarin have a significantly prolonged exposure to bleeding risk (even in the nonbleeding
patient), given the long half-life compared with direct oral anticoagulants. Vitamin K is
indicated if the international normalized ratio is significantly elevated, even in a nonbleeding
patient; factor replacement is generally not indicated in the nonbleeding patient. In addition,
recent cases of the drugs K2 or spice contaminated with synthetic vitamin K antagonists
with extraordinarily long half-lives should be noted and managed with guidance from a
poison control center or a toxicologist.52
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Reversal or replacement strategies may be indicated for nonbleeding anticoagulated patients
requiring an emergency procedure with significant bleeding risk (eg, ischemic bowel
requiring a laparotomy). Treatment decisions involve assessing the risk of procedural-related
bleeding without replacement or reversal, the risk of progression of illness requiring the
procedure should it be delayed, and the benefit of replacing or reversing the anticoagulant.
Considerations include the time of last anticoagulant dose and half-life and comorbidities
affecting metabolism and excretion, such as acute renal insufficiency for dabigatran or
edoxaban. The specific indication for anticoagulation should also be considered (eg,
prophylaxis for a mechanical heart valve versus nonvalvular atrial fibrillation, with
CHA2DS2-VASc [congestive heart failure, hypertension, age 75 years or older, disbetes
mellitus, stroke, transient ischemic attack or thromboembolism, vascular disease, age 65 to
74 years, sex category (female)] score of 2). If the risks of delay are sufficiently high and the
procedure urgently indicated while the anticoagulant is active, reversal or replacement may
be indicated and follows the same decision tree as is used for the bleeding patient.38,53–55
Andexanet alfa (as distinct from idarucizumab and 4-factor prothrombin complex
concentrate) is not currently FDA approved for nonbleeding patients requiring urgent or
emergency procedures or surgeries.

Ann Emerg Med. Author manuscript; available in PMC 2020 October 08.

Baugh et al.

Page 8

Author Manuscript

Finally, the timing of restarting anticoagulation after a bleeding episode is an important
consideration. It involves balancing the severity, location, and consequence of the bleeding
event with the indication of anticoagulation, associated thrombotic risk, and possibility of
rebleeding. The timing of resuming anticoagulation should be deferred to the inpatient
teams.

LIMITATIONS

Author Manuscript
Author Manuscript

Our approach had several limitations. First, we did not perform a systematic literature
review consistent with Preferred Reporting Items for Systematic Reviews and Meta-analyses
standards.56 Our process permitted discussion of best practices when evidence was lacking;
guidelines limited to systematic review were necessarily restricted to interventions with the
highest quality of evidence. Second, the topic of anticoagulation reversal or replacement is a
dynamic field that will continue to evolve. It is intended to be adaptable to local resource
availability (ie, access to specific reversal agents) and will require updating as the evidence
evolves. Third, a common criticism of expert panel recommendations is overrepresentation
by urban, academic physicians, which risks making the recommendations irrelevant to
clinicians practicing in different settings. Although we assembled a panel of clinicians from
academic and community settings, as well as urban and rural settings, by definition
consensus necessitated compromise. Fourth, these recommendations do not include a costbenefit analysis. This may be a consideration of treatment; however, the agents have been on
the market only a short time and data are lacking. Additionally, multiple confounders of
critically ill patients make cost-effectiveness data difficult to interpret. Future considerations
include price changes, new and generic agents, and new treatment options. Therefore, the
panel chose not to base recommendations on the relative expense of various treatment
options.

DISCUSSION
Our multidisciplinary expert panel developed a stepwise guidance framework to aid the
emergency physician’s approach to the anticoagulated patient who is bleeding or not
bleeding but requiring an emergency procedure. This framework provides interventions that
should be considered in all bleeding patients in parallel with a determination of whether the
patient is experiencing life-threatening or critical-site bleeding warranting the use of reversal
or replacement agents.
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There are 3 critical considerations in managing the bleeding patient receiving
anticoagulation: Is the bleeding event life threatening, is the site critical, and what are the
agent, dose, and most recent time received? The most widely used bleeding definitions come
from trial-based literature and are focused on research applications for a specific
anticoagulant, patient population, or both.25–31 The Bleeding Academic Research
Consortium definition used here is well suited to apply to anticoagulated patients likely to be
encountered in the ED.34 Additionally, reversal study definitions of inclusion criteria
reflected actual cases and are therefore useful as a bedside tool.42,53,57
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This guidance is intended to be a bedside tool for the physicians caring for these critically ill
patients. However, nuances were difficult to capture in the simplified format of the decision
tree. Definitions of life-threatening bleeding, critical sites, and emergency surgery or urgent
procedure in the nonbleeding patient warranting reversal or replacement are sensitive to
clinical context. Clinicians should carefully weigh the risks and benefits of the various
treatment options, with shared decision making among the patients, families, proxies, and
consulting physicians, and appreciate the subtleties of when replacement or reversal is or is
not indicated.58,59
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Emergency medicine involves a diversity of practice environments and resources, and
therefore this framework offers 2 tiers of recommendations. Tier 1 recommendations are
most aligned with FDA-approved indications and the highest quality of evidence supporting
their use. Tier 2 recommendations are offered as alternatives in circumstances in which tier 1
interventions are not available, have limited supporting data, and may be off label. Poison
control centers may serve as an additional resource to guide optimal transfer facility targets
based on availability of specific reversal agents.
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The available trial data supporting replacement and reversal agents and their costs have
generated controversy.60 The lack of a comparator arm in the REVERSE-AD (A Study of
the RE-VERSal Effects of Idarucizumab on Active Dabigatran) and ANNEXA-4
(Andexanet Alfa, a Novel Antidote to the anticoagulation Effects of Factor Xa Inhibitors)
trials, reports of thrombotic events in treated study subjects, and high cost of andexanet alfa
relative to prothrombin complex concentrates generated concerns.61,62 Ongoing
investigations aim to address several of these areas, but currently available data are limited.
63 Clinical efficacy was demonstrated in the REVERSE-AD and ANNEXA-4 trials but not
included in FDA labeling for andexanet alfa. Furthermore, thrombotic events after
anticoagulant reversal may be due to the patient’s intrinsic prothrombotic state, the bleeding
scenario, or the reversal agent. The thrombotic event rate confidence intervals of all the trials
overlap substantially; however, cross comparison of trials is complicated, given their
different designs. No thrombotic events occurred in healthy volunteers in phase 3 andexanet
alfa trials, and 9.7% experienced an event in the trial of 352 patients with major bleeding.61
Replacement strategies used before andexanet alfa’s availability (eg, prothrombin complex
concentrates) are prothrombotic.64 Andexanet alfa’s cost is significant; however, health
economic data are currently lacking.
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Use of replacement or reversal agents is only one component of care in these critically ill
patients. Treatment of the patient with a life-threatening bleeding event may likely require
other interventions, such as surgery, interventional radiology, or endoscopy procedures.
Specialty consultation to expedite these interventions should be requested in parallel with
other treatments. In settings in which patient transfer is required, this should be initiated as
early as possible. It may be beneficial to initiate replacement or reversal before transfer as
long as it does not prolong transfer for definitive care.
In conclusion, we developed a multidisciplinary anticoagulant reversal and replacement
guidance statement supported by literature and consensus definitions to support evaluation
and treatment of the bleeding patient and nonbleeding patient requiring emergency invasive

Ann Emerg Med. Author manuscript; available in PMC 2020 October 08.

Baugh et al.

Page 10

Author Manuscript

procedures. Emergency physicians encounter a majority of anticoagulation-associated
hemorrhages and should be supported by hospital resources to rapidly deploy evidencebased treatments. New resources such as reversal and replacement agents offer more
treatment options but increase the complexity of treatment decisions. Further research is
needed to answer key questions that could further clarify the role of specific reversal or
replacement agent treatment regimens to aid targeting of therapies to where they have the
most clinical influence.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Coagulation cascade, anticoagulants, and reversal or replacement targets.
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Figure 2.

Consensus anticoagulation reversal or replacement decision tree.* *Refer to Table 2 for
anticoagulant characteristics and Table 3 for dosing of reversal and replacement agents. AT,
Antithrombin; INR, international normalized ratio; PCC, prothrombin complex concentrate;
vit K, vitamin K; FFP, fresh frozen plasma. †Based on last dose inclusion criteria used for
clinical studies. ‡FDA approved for bleeding only (not emergency surgery/urgent
procedure). §Not FDA approved. ‖If tier 1 not available. ¶Includes 4-factor PCC (preferred),
3-factor PCC, and activated PCC.
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Figure 3.

Emergency treatment and supportive care interventions.
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Figure 4.

Consensus definitions of the expert panel.
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Figure 5.

Reassessment components after reversal or replacement.
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Profile of anticoagulant reversal panel experts.
Discipline or Specialty*

No. of Participants

Emergency medicine (academic)

6

Emergency medicine (community)

6

Cardiology (general)

2

Toxicology

1

Surgery

1

Neurointensivist

1

Hematology/transfusion medicine

1

Intern ist/thrombologist

†

1

Author Manuscript

Pharmacy

1

Advanced-practice provider

1

*

Some panelists were counted in multiple categories.

†

A thrombologist is a new role for a physician who has developed expertise in anticoagulation and venous thromboembolism management
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‡

VTE prophylaxis

VTE, VTE
prophylaxis

NVAF and valvular
atrial fibrillation,
VTE, ACS, critical
limb ischemia, DIC

VTE, VTE
prophylaxis,
STEMI, unstable
angina, and non-Qwave MI,
mechanical heart
valve prophylaxis

Betrixaban

Fonda parinux

Unfractionated
heparin

Enoxaparin

Edoxaban

NVAF, VTE

NVAF, VTE, VTE
prophylaxis

Apixaban

‡

NVAF, VTE, VTE
prophylaxis,
chronic CAD or
PAD

NVAF, VTE, VTE
prophylaxis

Rivaroxaban

Dabigatran

FDA Indications

Ann Emerg Med. Author manuscript; available in PMC 2020 October 08.
VTE: 1 mg/kg SQ bid or 1.5 mg/kg SQ qd
VTE prophylaxis (THR/TKR/abdominal surgery/medical): 30
or 40 mg SQ qd; 30 mg SQ every 12 h
STEMI: 30-mg IV bolus followed 15 min later by 1 mg/kg
SQ, MAX 100 mg for the first 2 doses; maintenance, 1 mg/kg
SQ bid; plus aspirin or (RD for >75 y) 0.75 mg/kg SC every
12 h (maximum 75 mg for the first 2 doses) only) followed by
0.75 mg/kg dosing for the remaining doses
Unstable angina and non‒Q‒wave MI: mechanical heart
valve: 40 mg SQ every 24 h OR 1 mg/kg SQ bid (say off
label?)

NVAF and valvular atrial fibrillation: 70–80 units/kg IV bolus
followed by infusion of 18 units/kg per hour or fixed dose of
5,000 units IV bolus followed by infusion of 1,000 units/h
VTE: 80 units/kg IV bolus and then 18 units/kg per hour, or
fixed dosing of 5,000 units IV bolus followed by 1,000 units/h
VTE prophylaxis: 5,000 units SQ every 8–12 h
ACS: 60 units/kg (maximum 4,000 units) followed by an
initial infusion of 12 units/kg per hour (maximum 1,000
units/h)
DIC: Initial, 10,000 units IV bolus and then 5,000 to 10,000
units every 4–6 h

VTE: 5–10 mgSQqd VTE prophylaxis (THR/TKR/hip
fracture, abdominal surgery): 2.5 mg SQ qd

VTE prophylaxis: 160 mg PO ×l followed by 80 mg PO qd,
(RD) 80 mg ×l followed 40 mg qd

NVAF: 60 mg PO qd, (RD) 30 mg qd VTE: 60 mg PO qd,
(RD) 30 mg qd

NVAF: 5 mg PO bid, (RD) 2.5 mg PO bid VTE: 10 mg PO bid
×7 days followed by 5 mg PO bid VTE primary (THR/TKR)
or secondary prophylaxis: 2.5 mg PO bid

NVAF: 20 mg PO qd, (RD) 15 mg PO qd VTE: 15 mg PO bid
×21 days followed by 20 mg qd VTE primary (THR/TKR) or
secondary prophylaxis: 10 mg qd Chronic CAD or PAD: 2.5
mg PO bid plus aspirin

NVAF: 150 mg PO bid, (RD) 75 mg PO bid VTE: 150 mg PO
bid VTE prophylaxis: 150 mg PO bid (after THR 110 mg PO
× 1 followed by 220 mg PO qd)

Dosing*

Author Manuscript

Drug

AT-dependent
(mediated) selective
inhibition of Xa and to
a lesser extent
thrombin (IIa)

AT-dependent
(mediated) inactivation
of thrombin (IIa) and
activated factor X
(factor Xa)

AT–dependent
(mediated) selective
inhibition of Xa

Direct Xa inhibitor

Direct Xa inhibitor

Direct Xa inhibitor

Direct Xa inhibitor

Direct thrombin
inhibitor

Mechanism

Author Manuscript

Anticoagulant characteristics.

4.5–7.5
h SQ, 2–
4 h IV

1.5 h

17–21 h

19–27 h

11.5 h

6.8–15.2
h

5–11.7 h

12–17 h

Halflife*

Hepatic: primary by
desulfation or
depolymerization
8%−40% renal clearance

Hepatic and
reticuloendothelial system
Renally cleared only at
higher doses; phagocytosis

77% renal clearance

Substrate of P-glycoprotein
6%−13% renal clearance

Hepatic: minimal, substrate
of P-glycoprotein and
CYP3A4 50% renal
clearance

Hepatic: mainly by
CYP3A4 25% renal
clearance

Hepatic: primary site by
CYP3A4/5, CYP2J2, and
hydrolysis 33% renal
clearance

Hydrolyzed to form
dabigatran, the active
moiety, further metabolized
through conjugation 80%
renal clearance

Metabolism and Renal
Clearance

↔ PT/INR, ↔/↑
PTT,
↑anti-Xa level

↔ PT/INR, PTT,
↑anti-Xa level

↔ PT/INR, ↔/↑
PTT, ↑anti-Xa level

↔/↑ PT/INR, ↔/↑
PTT, ↑anti-Xa level

↑ PT/INR, ↔/↑ PTT,
↑anti-Xa level

↑ PT/INR, ↔/↑ PTT,
↑anti-Xa level

↑↑ PT/INR, ↔/
↑PTT, ↑anti-Xa level

↔/↑PT/INR, ↑↑
PTT, ECT/dTT, TT,
↔ anti-Xa level

Laboratory
†
Effects

Author Manuscript
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NVAF and valvular
atrial fibrillation,
VTE, VTE
prophylaxis (THR/
TKR), mechanical
heart valve
prophylaxis

NVAF and valvular atrial fibrillation: initial 2–5 mg PO qd;
adjust dose based on the results of INR
VTE and VTE prophylaxis (THR/TKR): initial 2 to 5 mg PO
qd; adjust dose based on the results of INR mechanical heart
valve: initial 2–5 mg PO qd; adjust dose based on the results
of INR

VTE in cancer: 200 IU/kg SQ QD ×l mo and then 150 IU/kg
SQ qd
VTE prophylaxis (THR/abdominal surgery/medical): 2,500–
5,000 IU SQ qd
UA/NQWMI: 120 IU/kgSQ every 12 h (max 10,000 IU/dose)
with concurrent aspirin
Blocks the
regeneration of vitamin
K epoxide, thus
inhibiting synthesis of
vitamin K-dependent
clotting factors, which
include factors II, VII,
IX, and X, and the
anticoagulant proteins
C and S proteins C and
S

AT-dependent
(mediated) selective
inhibition of Xa and to
a lesser extent
thrombin (IIa)

Mechanism

5–7 days

3–5 h

Halflife*

Hepatic: extensive by
CYP2C9 (primary
isoenzyme), CYP2C19,
CYP2C8, CYP2C18,
CYP1A2, and CYP3A4
92% renal clearance

NA
70% renal clearance

Metabolism and Renal
Clearance

↑PT/INR, ↔/↑ PTT,
anti-Xa level

↔ PT/INR,↔/↑PTT,
↑anti-Xa level

Laboratory
†
Effects

Requires initial parenteral agent bridge for treatment of acute VTE.

‡

Laboratory results are not useful unless correlated for a specific drug. Direct oral anticoagulants specifically have varying effects on PT/INR and other laboratory results. Bold up arrows indicate main/
significant impact to increase or alter lab result; up arrows indicate likely impact to increase or alter lab result; 2 up arrows indicate significant impact to increase or alter lab result; double sided horizontal
arrows indicate may or may not impact lab value; up arrows with double sided horizontal arrow indicates likely impact to increase or alter lab result but also may not alter result.

†

Assumes normal renal and hepatic function, normal body mass index, and half-lives extended significantly with renal or hepatic failure, depending on the drug.

*

NVAF, Nonvalvular atrial fibrillation; VTE, venous thromboembolism; PO, by mouth; bid, twice daily; RD, reduced dose; THR, total hip replacement; qd, once daily; PT, prothrombin time; ECT, Ecarin
clotting time; dTT, diluted thrombin time; CAD, coronary artery disease; PAD, peripheral arterial disease; TKR, total knee replacement; SQ, subcutaneous; ACS, acute coronary syndrome; DIC,
disseminated intravascular coagulation; IV, intravenous; STEMI, ST-segment elevation myocardial infarction; MI, myocardial infarction; IU, international unit; NQWMI, non-Q-wave myocardial infarction;
NA, not applicable.

Warfarin

‡

VTE prophylaxis,
unstable angina,
and non-Q-wave
MI, mechanical
heart valve
prophylaxis

Author Manuscript

Dalteparin

Author Manuscript
Dosing*

Author Manuscript

FDA Indications

Author Manuscript

Drug
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4‒factor PCC
(Kcentra in the
US)

Approved use:
vitamin K
antagonists
(warfarin)
Nonapproved use:
DOACs

UFH and LMWH
(enoxaparin,
dalteparin)

Protamine

‡

Direct factor Xa
inhibitors (apixaban
and rivaroxaban)

Andexanet alfa

Replacement

Direct thrombin
(factor IIa) inhibitor
(dabigatran)

Idarucizumab

Reversal

Drug

Varies

1–6 h
(unfractionated
heparin); SQ
doses of UFH
take longer to
Absorb
3–12 h (lowmolecular‒
weight heparin);
SQ doses of
LMWH take
longer to absorb

<18 h

<8–12 h

Administration
Window*

Contains nonactivated
vitamin K-dependent
coagulation factors II,
VII, IX, and X, and
antithrombotic protein C
and protein S, heparin,
albumin

A weak anticoagulant
that binds heparin and
forms inactive complex

Recombinant modified
human factor Xa
(activated factor X)
molecule, which acts as
a decoy by reversibly
binding to factor Xa
inhibitors, thereby
reducing their
availability to act on
endogenous factor Xa

Humanized monoclonal
antibody fragment;
neutralizes the
anticoagulant effect of
dabigatran by
irreversibly binding to it
and its metabolites

Mechanism

Author Manuscript
Reversal or
Replacement
Target

Urgent reversal of vitamin
K antagonist therapy for
treatment of major
bleeding, surgical
procedures, or both

Neutralization of heparin or
low-molecular-weight
heparin

Life-threatening or
uncontrolled bleeding
Specific for direct factor Xa
inhibitors, approved only
for apixaban and
rivaroxaban

Life‒threatening bleeding
Need emergency surgery/
urgent invasive procedure
Specific for dabigatran

FDA Indications

Factor
dependent:
4.2–59.7 h

5–7 h

9.5–10.8 h

Half-life

Author Manuscript

Reversal and factor replacement agent characteristics.

Warfarin: individualize dose by
INR and IBW: INR-based 25–
50 IU/kg IV, max 2,500–5,000
IU with concurrent vitamin K
or 1,500 IU ×l; may repeat 500
units if bleeding continues
DOACs: life ‒ threatening or

Heparin: 1 mg of protamine
will neutralize not less than 100
units of heparin; slow IV
injection during 10 min, up to
max of 50 mg/dose Dalteparin:
1 mg IV for every 100 anti-Xa
IU of dalteparin Enoxaparin: 1
mg IV for every 1 mg of
enoxaparin administered in the
previous 8 h; if >8 h has
elapsed since the last dose, a
second infusion of 0.5 mg per 1
mg of enoxaparin may be given

Low dose: ≥8 h since last dose
or ≤ 5 mg of apixaban or ≤10
mg of rivaroxaban Initial IV
bolus: 400 mg; target infusion
rate of 30 mg/min; then IV
infusion: 4 mg/min for up to
120 min
High dose: <8 h since last dose
or unknown and >5 mg of
apixaban or >10 mg of
rivaroxaban Initial IV
bolus: 800 mg; target infusion
rate of 30 mg/min; then IV
infusion: 8 mg/min for up to
120 min

5–g (2 × 2.5 g vials) IV bolus

Dosing Regimen

Warfarin: coadminister
with IV vitamin K DOAC:
a median (interquartile
range) dose of 2,000 IU
(1,500–2,000 IU) typically
given with less or more
needed for patients under

≈ $10 to $133 per
administration (50– to
450–mg range, with higher
range representing average
dosing in cardiothoracic
surgery patients for UFH
reversal)

Low vs high dose based on
timing from last dose and
dosage amount of Xa
inhibitor May need to
redose, although no
clinical data currently exist
Low dose: ≈ $33,000 per
administration High dose:
≈ $59,400 per
administration

Redosing was used in
≈2% of patients ≈ $4,452
per administration

Special Considerations
†
and Cost

Author Manuscript
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Vitamin K
antagonists
(warfarin)

Vitamin K
antagonists
(warfarin)

Fresh frozen
plasma

Approved use:
factor replacement
patients with
hereditary factors
VIII and IX
deficiency and
nonhemophiliacs
with acquired
inhibitors to factors
VIII, IX, and XI
Nonapproved use:
surgical
coagulopathy such
as trauma or
cardiothoracic;
DOAC bleeding
reversal

DOAC reversal

†

Factor replacement
in patients with
hemophilia B Not
recommended for

Vitamin K

aPCC (FEIBA
in the US)

‡

3-factor PCC
(Profilnine SD
and Bebulin
VH in the US)

‡

Author Manuscript

Reversal
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Varies

Varies

Varies

Varies

Comprised plasma
proteins such as
albumin,

Vitamin necessary for
the hepatic synthesis of
factors II, VII, IX, and
X Cofactor for a
microsomal enzyme that
triggers the
posttranslational
carboxylation of
peptide‒bound glutamic
acid residues into active
coagulation factor

Contains II, VII, IX, and
X with primarily
activated factor VII and
nonactive factors II, IX,
and X

Contains factors II, IX,
and X

Mechanism

Author Manuscript
Administration
Window*

Acquired combined
coagulation factor
deficiency caused by liver

Acquired
hypoprothrombinemia and
hypoprothrombinemia
secondary to anticoagulant

Hemorrhage in patients
with hereditary factor VII
and IX deficiency disease
with inhibitor; both for
prophylaxis preprocedure
and for active bleeding

Hemorrhage in patients
with hemophilia B

FDA Indications

NA

NA

72 h (factor
II)

24–32 h

Half-life

Author Manuscript

Drug

10–15 mL/kg IV for
replacement of coagulation

Nonbleeding patients: 2.5–25
mg PO to decrease INR
Major bleeding: 5 to 10 mg
slow IV injection, in
addition to 4-factor PCC

Maximum: single dose, 100
units/kg; daily dose, 200
units/kg DOACs: Life‒
threatening or critical site: 10–
25 units/kg and repeated dose
in 1–2 h if bleeding continues
or if clinically indicated. May
consider 50 units/kg up to a
suggested maximum of 100
units/kg Nonlife‒threatening or
noncritical site: 10 units/kg ×l
and repeated dose in 1–2 h if
bleeding continues

No. of factor IX IU
required=body weight (kg) ×
desired factor IX increase (%)
×l IU/kg

critical site: 10–25 units/kg and
repeated dose in 1–2 h if
bleeding continues or if
clinically indicated. May
consider 50 units/kg up to a
suggested maximum of 100
units/kg Nonlife‒threatening or
noncritical site: 10 units/kg ×l
and repeated dose in 1–2 h if
bleeding continues

Dosing Regimen

Thawing requires 15–30
min, depending on the
quantity Likely ineffective

Initial onset typically 3–6
h if given IV; maximal
initial effect on INR
usually occurs in ≈16–20
h For bleeding patients
receiving warfarin, give
vitamin K first and before
4F‒PCC (Kcentra) if 4F‒
PCC used Oral: ≈ $67 to
$353 per administration
(5–25 mg PO) IV: $135 to
$270 per administration
(5–10 mg IV)

≈ $4,725 to $18,900 per
administration (25–100
units/kg=1,750 to 7,000
units)

Not recommended for
DOAC reversal ≈$2,818 to
$11,270 per administration
(25–100 units/kg=1,750–
7,000 units)

or over 65 kg, respectively.
Contains heparin so
should not be used in
patients with confirmed or
strongly suspected HIT z
$5,075 to $20,300 per
administration (25–100
units/kg=1,750 − 7,000
units)

Special Considerations
†
and Cost

Author Manuscript

Reversal or
Replacement
Target
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NA

Competitive inhibitor of
plasminogen activation

immunoglobulins,
coagulation factors,
complement proteins,
and protease inhibitors

IV: patients with
hemophilia for short-term
use to reduce or prevent
hemorrhage and reduce the
need for replacement
therapy during and after
tooth extraction
Oral: heavy cyclic
menstrual bleeding

disease, or undergoing
cardiac surgery or liver
transplant TTP

FDA Indications

IV: 2 h PO:
11 h

Half-life

Trauma: 1,000 mg administered
IV during 10 min, followed by
1,000 mg infused during the
subsequent 8 h

factors in patients with acquired
deficiencies

Dosing Regimen

≈ $18 to $174 per
administration (1,000–
2,000 mg)

for DOAC reversal ≈$168
per administration (4
units)

Special Considerations
†
and Cost

Assumes normal renal and hepatic function and normal body mass index.

Dosing of PCC/aPCC products is expressed as units of factor IX.

‡

Cost based on typical initial administration for a 70-kg patient, according to the Medi-Span Average Wholesale Price as of June 2019. FFP price is based on a cost of $41.95 per unit (from Shander et al
65).

†

*

UFH, Unfractionated heparin; LMWH, low-molecular-weight heparin; US, United States; DOAC, direct oral anticoagulant; aPCC, activated prothrombin complex concentrate; TTP, thrombotic
thrombocytopenic purpura.

Tranexamic
acid

Other

Not drug specific

Author Manuscript

Reversal

Mechanism

Author Manuscript
Administration
Window*

Author Manuscript

Drug

Author Manuscript

Reversal or
Replacement
Target
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